Blog

The latest thoughts from Medicines Law & Policy partners.

WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument

In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...

Corbyn’s Compulsory Licenses. Will they work?

On 24 September, Jeremy Corbyn, leader of the UK Labour party, announced a series of measures to bring medicines pricing in check and to...

Humiragate: AbbVie’s desperate attempts to keep its monopoly

A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...

The European Commission says Covid-19 vaccines should be global public goods, but do their...

The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is concluding negotiations with two companies....

Dutch health insurance company Menzis takes AstraZeneca to court over patent evergreening

Today health insurance company Menzis announced  that it is taking the pharmaceutical company AstraZeneca to court over the pricing of Seroquel, a medicine...

Some Surprises in the European Commission’s New Intellectual Property Strategy

The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...

New Dutch Foundation to Address High Medicines Pricing Announces Plan to File Complaint with...

The newly established Dutch Pharmaceutical Accountability Foundation has announced its first action to address unreasonably high medicines prices in the Netherlands. The Foundation will...
wine glass half full

Transfer of technology and know-how for the production of pandemic-related health products in the...

A version of this brief was published on 13 June '25 by the Graduate Institute as part of their 'Governing Pandemic Snapshot' series: https://www.governingpandemics.org/gp-snapshot During...

European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to Protect European Patients...

On 11 May 2018, US President Trump announced his plans to lower drug prices in America. Under the banner "American Patients First" he outlined...

High medicines prices in Europe – do not Brexit the people

The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...